Biotech Stock News - Depomed

. . . Lower side effects - Drug maker Depomed (NasdaqNM:DEPO) received Food and Drug Administration approval for its antibiotic Proquin XR to treat uncomplicated urinary tract infections. While similar to Bayer AG's Cipro, Depomed's Proquin lists nausea and diarrhea as uncommon side effects rather than common side effects. The difference may be that Proquin's dosage is released over 6 hours instead of about 2 hours with Cipro, decreasing the side effects. The company believes that lower incidence of side effects will increase adherence to the treatment.
From: InvestingIN Biotech